Recent Updates
Recently added Catalysts
SBC Positive Sentiment

SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age

Key Takeaway: SBC Medical Group Holdings has begun developing a DNA methylation test to estimate biological age. This initiative will be managed by its subsidiary, SBC AI Longevity Innovation, Inc. The test aims to leverage advanced analysis techniques to provide insights into individual biological aging.

Market Sentiment Analysis

POSITIVE FACTORS

  • SBC Medical initiates innovative test development.
  • Focus on DNA methylation analysis for biological age.
  • Led by AI and longevity-focused subsidiary.

Full Press Release Details

IRVINE, Calif.--(BUSINESS WIRE)-- #BiologicalAge--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it has commenced in-house development of a test designed to estimate an individual’s biological age using DNA methylation analysis. Development will be led by the Company’s AI and longevity-focused subsidiary, SBC AI Longevity Innovation, Inc. The

Frequently Asked Questions

What is the purpose of the DNA methylation test?

The test estimates an individual's biological age.

Which subsidiary is leading the test development?

SBC AI Longevity Innovation, Inc. is leading the development.

Where is SBC Medical Group Holdings based?

The company is based in Irvine, California.

What technology does the test utilize?

It uses DNA methylation analysis for its estimates.

Last updated: Oct 22, 2026